iBio (NYSEMKT:IBIO) Trading Down 2.3% – What’s Next?

iBio, Inc. (NYSEMKT:IBIO) dropped 2.3% on Monday . The company traded as low as $2.06 and last traded at $2.10. Approximately 1,151,783 shares were traded during mid-day trading, an increase of 917% from the average daily volume of 113,212 shares. The stock had previously closed at $2.15.

iBio Trading Up 9.5%

The business has a 50-day moving average of $1.94 and a 200-day moving average of $1.28. The company has a quick ratio of 0.91, a current ratio of 0.91 and a debt-to-equity ratio of 0.04. The stock has a market cap of $51.72 million, a price-to-earnings ratio of -1.65 and a beta of 1.14.

About iBio

iBio, Inc is a clinical-stage biotechnology company that develops recombinant proteins and vaccine candidates using proprietary plant-based expression systems. Headquartered in Bryan, Texas, the company leverages its Fast Expression System Technology (FAST) and LAMP™ molecular farming platforms to accelerate the design and production of complex biologics. These platforms capitalize on Nicotiana benthamiana plants as biofactories, enabling rapid, scalable expression of target proteins without the need for mammalian cell cultures.

The company’s pipeline includes vaccine candidates against viral pathogens and therapeutic proteins for immuno-oncology and infectious diseases.